Q3 FY2026 · ended Sep 30, 2026 · Revenue $39.55M, -20.4% YoY · Filed Oct 28, 2026
Amarin Corp Plc\uk (AMRN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $39.5 million and net income of $245,000. As of Sep 30, 2026 it held $323.4 million in cash and investments and $7.6 million in total debt.
Revenue
$39.55M
-20.4% vs year-ago quarter
Net income
$245,000
+103.2% vs year-ago quarter
Operating cash flow
$9.22M
+172.6% vs year-ago quarter
Free cash flow
—
EPS
$0.00
+100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
421.63M
+1.4% vs year-ago quarter
Net cash
$315.78M
Q3 FY2026
Operating margin
-18.2%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Dublin 2
- SEC filer status
- Accelerated filer
- SEC CIK
- 897448
- Former names
- AMARIN CORP PLC\UK (until Oct 28, 2026); AMARIN PHARMACEUTICALS PLC (until Jul 13, 2000); ETHICAL HOLDINGS PLC (until Jan 28, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $39.5M | $42.2M | $45.1M | $49.2M | $49.7M |
| Operating income | -$2.4M | -$12.0M | -$11.3M | -$6.3M | -$11.1M |
| Net income | $245,000 | -$7.7M | -$10.5M | -$1.2M | -$7.7M |
| Diluted EPS | $0.00 | -$0.02 | -$0.03 | -$0.00 | -$0.02 |
| Operating cash flow | $9.2M | $6.6M | $6.4M | $15.3M | -$12.7M |
| Total assets | $634.1M | $624.4M | $645.8M | $670.8M | $659.8M |
| Total liabilities | $189.7M | $180.7M | $196.4M | $211.5M | $200.9M |
| Stockholders' equity | $444.4M | $443.6M | $449.4M | $459.3M | $458.9M |
| Cash and investments | $323.4M | $314.6M | $307.8M | $302.6M | $286.6M |
| Total debt | $7.6M | $7.2M | $7.7M | $8.2M | $9.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 15, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | Apr 29, 2026 | Mar 31, 2026 |
All 1003 Amarin Corp Plc\uk SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.